Literature DB >> 11427263

Staphylococcus aureus capsular polysaccharide type 5 conjugate and whole cell vaccines stimulate antibody responses in cattle.

T Tollersrud1, L Zernichow, S R Andersen, K Kenny, A Lund.   

Abstract

Dairy heifers were immunized subcutaneously with one of four different vaccines which contained preparations of Staphylococcus aureus capsular polysaccharide type 5 (CP5) and a mineral oil adjuvant, or received a placebo containing saline and adjuvant. The vaccine containing a CP5-human serum albumin conjugate (CP5-HSA) and the vaccine with formaldehyde inactivated whole cells expressing CP5, both elicited strong anti-CP5 antibody responses. After two injections three weeks apart and a third injection 10 months later, the mean level and duration of the anti-CP5 antibody response was significantly higher in the whole cell group. No differences were found between the two groups with regard to the relative proportion of IgG subclasses, and the antibody responses to the polysaccharide were composed of both the IgG1 and IgG2. Vaccines containing only free CP5 or CP5 mixed with HSA produced weak and transient humoral immune responses. Only animals vaccinated with the whole cell vaccine or the conjugate vaccine showed responses to CP5 in a lymphocyte proliferation assay conducted one year after the third vaccination. This study indicates that CP5 expressed on the surface of formaldehyde inactivated whole cells, emulsified in an oil adjuvant, gives a strong and long lasting immune response in cattle. The use of conjugation technology, although effective, might not be necessary in order to achieve an immune response against S. aureus CP5 in cattle.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427263     DOI: 10.1016/s0264-410x(01)00124-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  10 in total

1.  Staphylococcus aureus capsular polysaccharide types 5 and 8 reduce killing by bovine neutrophils in vitro.

Authors:  Annette H Kampen; Tore Tollersrud; Arve Lund
Journal:  Infect Immun       Date:  2005-03       Impact factor: 3.441

2.  Evaluation of clumping factor A binding region A in a subunit vaccine against Staphylococcus aureus-induced mastitis in mice.

Authors:  Rui Gong; Changmin Hu; Haiyang Xu; Aizhen Guo; Huanchun Chen; Guangzhi Zhang; Lei Shi
Journal:  Clin Vaccine Immunol       Date:  2010-09-08

3.  Effect of a trivalent vaccine against Staphylococcus aureus mastitis lymphocyte subpopulations, antibody production, and neutrophil phagocytosis.

Authors:  Jai-Wei Lee; Celia N O'Brien; Albert J Guidry; Max J Paape; Kimberley A Shafer-Weaver; X Zhao
Journal:  Can J Vet Res       Date:  2005-01       Impact factor: 1.310

4.  Survey of potential factors involved in the low frequency of CP5 and CP8 expression in Staphylococcus aureus isolates from mastitis of dairy cattle from Argentina, Chile, and Uruguay.

Authors:  Maria Belen Ambroggio; Melina Soledad Perrig; Cecilia Camussone; Nazarena Pujato; Alicia Bertón; Edgardo Gianneechini; Silvia Alvarez; Ivan Sergio Marcipar; Luis Fernando Calvinho; Maria Sol Barbagelata
Journal:  J Appl Genet       Date:  2018-05-03       Impact factor: 3.240

Review 5.  Staphylococcus aureus capsular polysaccharides.

Authors:  Katherine O'Riordan; Jean C Lee
Journal:  Clin Microbiol Rev       Date:  2004-01       Impact factor: 26.132

6.  Protection from Staphylococcus aureus mastitis associated with poly-N-acetyl beta-1,6 glucosamine specific antibody production using biofilm-embedded bacteria.

Authors:  M M Pérez; A Prenafeta; J Valle; J Penadés; C Rota; C Solano; J Marco; M J Grilló; I Lasa; J M Irache; T Maira-Litran; J Jiménez-Barbero; L Costa; G B Pier; D de Andrés; B Amorena
Journal:  Vaccine       Date:  2009-02-12       Impact factor: 3.641

Review 7.  Staphylococcus aureus Vaccine Research and Development: The Past, Present and Future, Including Novel Therapeutic Strategies.

Authors:  Jonah Clegg; Elisabetta Soldaini; Rachel M McLoughlin; Stephen Rittenhouse; Fabio Bagnoli; Sanjay Phogat
Journal:  Front Immunol       Date:  2021-07-07       Impact factor: 7.561

8.  Lambs immunized with an inactivated variant of Anaplasma phagocytophilum.

Authors:  Snorre Stuen; Wenche Okstad; Karin Artursson; Basima Al-Khedery; Anthony Barbet; Erik G Granquist
Journal:  Acta Vet Scand       Date:  2015-07-25       Impact factor: 1.695

Review 9.  Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines.

Authors:  Peter Klein Klouwenberg; Louis Bont
Journal:  Clin Dev Immunol       Date:  2008

10.  Immunization routes in cattle impact the levels and neutralizing capacity of antibodies induced against S. aureus immune evasion proteins.

Authors:  Eveline Boerhout; Manouk Vrieling; Lindert Benedictus; Ineke Daemen; Lars Ravesloot; Victor Rutten; Piet Nuijten; Jos van Strijp; Ad Koets; Susanne Eisenberg
Journal:  Vet Res       Date:  2015-09-28       Impact factor: 3.683

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.